Satoshi Sueoka

Satoshi Sueoka

Auto-generated profile, based on publicly available information

Satoshi Sueoka

Department of Surgery, Ichinomiya Municipal Hospital

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2021 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
SSSatoshi Sueoka
Satoshi Sueoka
SSShinsuke Sasada
Shinsuke Sasada
NMNorio Masumoto
Norio Masumoto
AEAkiko Emi
Akiko Emi
TKTakayuki Kadoya
Takayuki Kadoya
MOMorihito Okada
Morihito Okada

16 September 2015 in International Journal of Oncology
Verified
Journal Article
Open access
HTHaruyoshi Tanaka
Haruyoshi Tanaka
MKMitsuro Kanda
Mitsuro Kanda
MKMasahiko Koike
Masahiko Koike
NINaoki Iwata
Naoki Iwata
DSDai Shimizu
Dai Shimizu
YKYasuhiro Kodera
Yasuhiro Kodera
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

30 June 2015 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
KEKazuhiro Ezaka
Kazuhiro Ezaka
MKMitsuro Kanda
Mitsuro Kanda
HSHiroyuki Sugimoto
Hiroyuki Sugimoto
DSDai Shimizu
Dai Shimizu
HOHisaharu Oya
Hisaharu Oya
YKYasuhiro Kodera
Yasuhiro Kodera

28 May 2021 in Breast Cancer
Verified
Journal Article
Open access
PDF file
AAAi Amioka
Ai Amioka
TKTakayuki Kadoya
Takayuki Kadoya
SSSatoshi Sueoka
Satoshi Sueoka
YKYoshie Kobayashi
Yoshie Kobayashi
SSShinsuke Sasada
Shinsuke Sasada
MOMorihito Okada
Morihito Okada
Background: Previously, we reported that Wnt5a-positive breast cancer can be classified as estrogen receptor (ER)-positive breast cancer; its prognosis is worse than that of Wnt5a-negative breast cancer. This study aimed to investigate the mechanisms underlying the poor prognosis in Wnt5a-positive breast cancer patients. Methods: In total, 151 consecutive ER-positive breast cancer patients who underwent resection between January 2011 and February 2014 were enrolled. DNA microarray and pathway analyses were conducted using MCF-7 cells stably expressing Wnt5a [MCF-7/Wnt5a (+)]. Based on the outcomes, cell viability/drug sensitivity assays, and mutation analysis were performed using cell cultures and breast cancer tissues. The relationship between Wnt5a and the PI3K–AKT–mTOR signaling pathway was also examined. Results: The relapse-free survival rate in patients with Wnt5a-positive breast cancer was significantly lower than that in patients with Wnt5a-negative breast cancer (P = 0.047). DNA microarray data suggest that only the cytochrome P450 (CYP) pathway was significantly upregulated in MCF-7/Wnt5a (+) cells (P = 0.0440). Additionally, MCF-7/Wnt5a (+) cells displayed reduced sensitivity to the metabolic substrates of CYP, tamoxifen (P < 0.001), paclitaxel (P < 0.001), and cyclophosphamide (P < 0.001). Of note, PIK3CA mutations were not associated with the expression of Wnt5a in breast cancer tissue and culture cells. Conclusions: In ER-positive breast cancer, Wnt5a upregulates the CYP metabolic pathway and suppresses tamoxifen, paclitaxel, and cyclophosphamide resistance, all of the three, standard treatment methods for ER-positive breast cancer. Wnt5a is thus potentially involved in the poor prognosis of ER-positive breast cancer independently of the PI3K–AKT–mTOR signaling pathway.

1 September 2022 in The Japanese Journal of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
MSMiyu Shinozuka
Miyu Shinozuka
MSMitsuru Sakai
Mitsuru Sakai
THTaichi Hirayama
Taichi Hirayama
MTMikinori Takashima
Mikinori Takashima
RSRyota Suzuki
Ryota Suzuki
KNKosei Nakajima
Kosei Nakajima
症例は83歳の女性で,上行結腸癌術後5年目に行った造影CTにて,肝S5とS4にまたがる部位に動脈相で軽度造影され門脈相で肝実質よりも弱い造影効果を呈する14 mm大の腫瘍を認めた.肝原発の悪性腫瘍もしくは転移性腫瘍を否定できず,腹腔鏡下肝S5・S4a区域切除術を施行した.病理組織学的検査ではリンパ上皮腫様癌を認め,全身検索にて原発巣となりうる病変が確認されなかったことから肝原発と診断した.術後1年目のCTにて肝十二指腸間膜近傍に43 mm大のリンパ節腫大を認めた.超音波内視鏡下生検の結果,リンパ上皮腫様癌の転移と診断した.他に明らかな転移所見を認めずリンパ節再発巣に対して放射線治療を施行した.治療後,腫瘍は消失し,以後6か月間再発を認めていない.肝原発リンパ上皮腫様癌は非常にまれであり,その治療方針は確立されていない.今後の症例の集積が待たれる.